PharmaVentures Podcast Series, Edition 12

Once you have identified an asset you want to acquire or partner, what happens next?

In this podcast, Ralph Hughes takes the listener through the process of commercial due diligence and evaluation, including the key stakeholders and insights needed to understand whether the asset is going to achieve strong performance in the marketplace.

Ralph talks to Adrian Dawkes about the different components involved in pre- and full- commercial due diligence:

• Understanding KOLs and payer perspectives to help you define market positioning and pricing.
• Getting the right subject matter expertise.
• The importance of a robust forecast and valuation on which to base the commercial launch strategy.
• How best to communicate data to reduce uncertainty and risk.
• Overcoming the challenges of getting in-depth due diligence done quickly.

 About the Interviewee:

Ralph Hughes is a Vice President at PharmaVentures with experience in Pricing and Market Access and Commercial and Business Development.

He has held various roles in the pharmaceutical industry. For Mundipharma, he developed the commercial and market access strategy for development and launch assets. At Pfizer, he developed market access and pricing strategies across the globe and across multiple disease areas for both early, late stage and in-market assets. He has delivered marketing campaigns, global forecasts, HTAs, pricing strategies, real world data studies, and economic models; through this, Ralph has a deep understanding of what it takes to commercialise an asset in the pharmaceutical industry. He holds a MSc in Public Health and Health Economics from the London School of Hygiene and Tropical Medicine and a BSc in Biomedical Sciences from Newcastle.

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

PharmaVentures Podcast Series, Edition 11

Listen as Andrew Guise gives key insight into the deal making landscape – asset value, accessing the market, positioning and the actual deal process in the current economic climate – from the unique position standing astride both the financial world and the technical world translating science into value.

About the Interviewee:

Andrew Guise is a Managing Director at PharmaVentures and is a member of the Corporate Advisory Team.

Andrew is a highly accomplished executive with a wealth of experience in finance, business development, and leadership. Notable deals including IPOs for IsoTis, Genmab and Thrombogenics, secondaries for Serono ($4bn), divestments of, St Martins Healthcare (hospitals), Degussa Dental, Synthes Stratec (ortho), Plasso to Becton Dickenson (lab supply), Oxxon to Oxford Bio (immunotherapy), Surface Therapeutics to Serentis (dermatology), Zyentia to Lonza (protein refolding). Andrew has held Board positions at Oxford Biosensors (POC diag), Oxitec (pest control), Prolysis (anti -infectives), Purity Health (reformulation), and Gaia Biotherapeutics (cannabinoids).

During his professional career Andrew has acted as advisor (SME to FTSE 100), VC investor, and held Board / C suite roles in a number of life science companies across multiple sectors.  Andrew has over 30 years’ experience in all areas of healthcare. Andrew holds a BEng in Biochemical Engineering and a PhD in Protein Refolding.

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

Listen as Frank Dollard, Steve Garland and Jansen Jacob discuss the ways in which pharma and biotech companies are getting control back over their supply chain and the opportunities they are seeing from best practice;  how the importance of quality and efficiency, including moves towards new low-cost regions in the West, are reducing risk for manufacturers whilst governments are trying to squeeze costs to meet the needs of a larger proportion of people requiring more medicines.

About the Interviewees:

Frank Dollard is a Senior Advisor at PharmaVentures.

Frank has a 40-year track-record of success and innovation in the Pharmaceutical Industry working for Glaxo, BMS and Pliva. His main experiences cover Manufacturing, Quality Management, Commercial, Supply-Chain and Procurement (Strategic Sourcing) within the ethical & generic pharmaceutical and devices industry. He has formed and led teams in Europe/USA/Latin America and the Pacific Rim. Frank is a chemistry graduate from the University of Liverpool. Since joining PharmaVentures, Frank has opined on multiple divestment projects, including the recent sale of Novartis’ manufacturing plants to Siegfried.

Steve Garland is an Expert Advisor at PharmaVentures.

With over 35 years’ experience in the biologics industry Steve’s career has covered the manufacturing, process development, business development and general management of vaccine (human and animal), recombinant proteins, monoclonal antibodies and cell and gene therapy product supply.  Steve has worked in both the CDMO and multi-product organisations and has extensive experience of microbial, yeast and mammalian cell culture systems ranging from less than 500mL to 12,000L scale using single use disposable and purpose designed and built stainless steel equipment.

A microbiologist by education Steve has lived and worked in the Netherlands.  He has led technology transfer projects into, out of and within the UK, has worked as a process expert on facility design and build within and without of the UK and has been process/facility lead on several M&A assignments.

Jansen Jacob is a Vice President at PharmaVentures.

Jansen is a healthcare transactions professional with nearly 20 years in the life science sector with expertise in M&A, licensing, business strategy, commercial due-diligence and deal structuring. At PharmaVentures, Jansen has played a key role in the divestment of manufacturing and R&D businesses on behalf of top 10 large pharmaceutical companies, resulting in multi-million dollar deals. Over the years he has also worked on a diverse range of assignments including licensing, valuation and strategy projects.

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

PharmaVentures Podcast Series, Edition 9

Listen as Fintan Walton, PharmaVentures’ CEO and Founder, discusses the 4 common mistakes being made in partnering and how to avoid them.

Fintan provides insight into how to achieve successful deal outcomes by avoiding risks along the clinical, commercial and regulatory pathway, and what fact-based data you need to get your drug to market with the right partner at the right price.

About the Interviewee:

Fintan Walton is the Founder and CEO of PharmaVentures. He has over 30 years’ experience helping clients achieve success in deal making.

Over a period of three decades, he has built it into a global player in supporting transactions for blue chip corporations and emerging innovator corporations. In that time, the firm has delivered more than 1,000 transaction related assignments for companies in 38 countries.

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

PharmaVentures Podcast Series, Edition 8

Listen as Ralph Hughes, PharmaVentures’ Pricing and Market Access expert, talks with Adrian Dawkes about how you can reduce the risk when you want to get your asset onto the market and get ahead of the competition.

• Understanding incentives, perspectives and funding flows can lead to better pricing and development strategies.
• Understanding payer perspectives can help you define market positioning and pricing.
• Targeting drug development at payers, as well as the regulators, can ensure adoption.
• Payers can become advocates, not blockers, given the right data and narrative.
• How combining pricing and market access with valuation work can increase investor confidence.

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

About the Interviewee:

Ralph Hughes is a Vice President at PharmaVentures with experience in Pricing and Market Access and Commercial and Business Development.

He has held various roles in the pharmaceutical industry. For Mundipharma, he developed the commercial and market access strategy for development and launch assets. At Pfizer, he developed market access and pricing strategies across the globe and across multiple disease areas for both early, late stage and in-market assets. He has delivered marketing campaigns, global forecasts, HTAs, pricing strategies, real world data studies, and economic models; through this, Ralph has a deep understanding of what it takes to commercialise an asset in the pharmaceutical industry. He holds a MSc in Public Health and Health Economics from the London School of Hygiene and Tropical Medicine and a BSc in Biomedical Sciences from Newcastle.

PharmaVentures Podcast Series, Edition 7

Listen as Ben Jacoby, Regulatory Expert, talks with Adrian Dawkes about the transition to the new regulations in Europe and UK:

• Can existing products continue to be sold?
• What will global manufacturers need to do?
• What is the impact for companion diagnostics being used alongside drugs in clinical trials?
• How is the environment in Great Britain different, and what does this mean for innovators?
• What’s the impact for patients?

A rare opportunity to hear from one of the most experienced regulatory advisors in this important space.

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

About the Interviewee:

Ben Jacoby is an experienced regulatory consultant who has worked with clients in the diagnostic, medical device and pharmaceutical industries to help them bring innovative products to market. He provides regulatory and strategic guidance on EU, UK and US issues to clients.

Ben has worked on European and UK medical device regulation.

Core competencies include: technical files, Clinical studies; EU and UK legislation including IVD’s, companion diagnostics and medical devices; EU legislative requirements for instruments; and classification of devices. With more than 25 years of experience in regulatory affairs, he was European-authorised representative at Ortho-Clinical Diagnostics (a Johnson & Johnson company at the time).

Ben has a PhD in Biochemistry from the University of London.